Novartis AG bolstered its portfolio of multiple sclerosis (MS) treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline PLC for up to US$1 billion, the company said.
Novartis, the Swiss pharmaceutical giant, acquired the rights this year to use the drug, ofatumumab, to treat cancer and sells it under the name Arzerra. This was part of a broader swap of assets completed in March, in which Novartis took over Glaxo’s cancer drugs and Glaxo took on much of Novartis’ vaccine business.
The deal announced on Friday gives Novartis all remaining rights to ofatumumab, which is being developed to treat relapsing, remitting multiple sclerosis and other autoimmune conditions.
Having the rights under one ownership would avoid the complications that could arise from having two companies selling the same drug for different uses. The deal also bolsters a portfolio of drugs Novartis is developing for multiple sclerosis, centered around its blockbuster pill Gilenya.
Novartis is to pay US$300 million upfront to Glaxo and another US$200 million once late-stage clinical trials start. Novartis would make payments of up to US$534 million on top of that, depending on whether development targets are reached. The company is also to pay royalties of up to 12 percent to Glaxo on any future net sales of the drug.
“Novartis is pleased to further reinforce our commitment to neuroscience and to add an exciting new treatment to our strong MS portfolio,” Novartis Pharmaceuticals division head David Epstein said in a news release.
In addition to Gilenya, Novartis sells a multiple sclerosis drug called Extavia and recently began marketing a generic version of Teva’s Copaxone, one of the most widely used drugs for the disease. It also has some other drugs in development. Gilenya could lose patent protection starting in 2019. So filling the loss could be another reason for Novartis to want a new drug.
However, the market for multiple sclerosis drugs is crowded, which might limit the sales any new drug like ofatumumab could have.
Moreover, ofatumumab is only now ready to enter late-stage clinical trials, putting it a couple of years behind ocrelizumab, a similar drug being developed by Roche.
Both drugs deplete B cells, which are white blood cells that are part of the immune system. B cells are necessary to fight infections, but if they go awry, they can contribute to autoimmune diseases like multiple sclerosis or to lymphomas. Both drugs bind to the same molecule on the surface of B cells — known as CD20 — as Roche’s big-selling cancer drug Rituxan. Rituxan is not approved for multiple sclerosis, but it is approved to treat rheumatoid arthritis, another autoimmune disease.
Ofatumumab, a type of protein called a monoclonal antibody, was developed initially by Genmab, a Danish biotechnology company, which receives royalties on sales.
David Redfern, the chief strategy officer at Glaxo, said in a news release that the sale would allow the company to focus on core areas, including HIV, oncology and vaccines.
“We are pleased to have completed this transaction to divest the remaining rights in ofatumumab, crystallizing significant additional value for GSK shareholders,” Redfern said.
The deal is expected to be completed by the end of the year.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last